Produktname:4-Bromo-1-cyclopropyl-1H-pyrazole

IUPAC Name:4-bromo-1-cyclopropyl-1H-pyrazole

CAS:1151802-23-1
Molekulare Formel:C6H7BrN2
Reinheit:95%+
Katalognummer:CM187743
Molekulargewicht:187.04

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM187743-1g in stock ƀț
CM187743-5g in stock ƦNJNJ
CM187743-10g in stock NJțɅ
CM187743-25g in stock ƀǧț

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:1151802-23-1
Molekulare Formel:C6H7BrN2
Schmelzpunkt:-
SMILES-Code:BrC1=CN(N=C1)C1CC1
Dichte:
Katalognummer:CM187743
Molekulargewicht:187.04
Siedepunkt:
Mdl-Nr.:MFCD18250639
Lagerung:Store at 2-8°C.

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.
Cyclopropanes
Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

Column Infos

Vebreltinib
Avistone announced that they received conditional approval from the National Medical Products Administration (NMPA) to commercialize Vebreltinib (Bozitinib) to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) in China. The conditional approval was based on results from a pivotal Phase II KUNPENG study with an objective response rate (ORR) of 75.0% and median progression-free survival (PFS) in patients with advanced METex14 mutations to 14.1 months with a good safety profile as was recently presented at the 2023 European Society for Clinical Oncology (ESMO) Congress in Madrid, Spain. Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-Met Tyrosine Kinase Inhibitor (TKI).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.